Your search returned 7 results.

Results
	1.	BAY 81-8973, a full-length recombinant factor VIII: Human heat shock protein 70 improves the manufacturing process without affecting clinical safety. [electronic resource] by Maas Enriquez, Monika Thrift, John Garger, Stephen Katterle, Yvonne Producer: 20170630 In: Protein expression and purification vol. 127 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	2.	Sucrose-Formulated Recombinant Factor VIII Dosing Flexibility in Prophylaxis Regimens: Experience from Postmarketing Surveillance Studies. [electronic resource] by Humphries, Thomas J Rauchensteiner, Stephan Tückmantel, Claudia Pieper, Alexander Maas Enriquez, Monika Mathew, Prasad Producer: 20150911 In: Advances in hematology vol. 2015 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	3.	Efficacy and safety of prophylaxis with once-weekly BAY 79-4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients. A randomised, active-controlled, double-blind study. [electronic resource] by Powell, Jerry Martinowitz, Uri Windyga, Jerzy Di Minno, Giovanni Hellmann, Andrzej Pabinger, Ingrid Maas Enriquez, Monika Schwartz, Lawrence Ingerslev, Jørgen Producer: 20130418 In: Thrombosis and haemostasis vol. 108 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	4.	Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting. [electronic resource] by Musso, Roberto Santagostino, Elena Faradji, Albert Iorio, Alfonso van der Meer, Jan Ingerslev, Jørgen Lambert, Thierry Maas-Enriquez, Monika Gorina, Eduard Producer: 20080221 In: Thrombosis and haemostasis vol. 99 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	5.	Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A. [electronic resource] by Pocoski, Jennifer Li, Nanxin Ayyagari, Rajeev Church, Nikki Maas Enriquez, Monika Xiang, Quer Kelkar, Sneha Du, Ella X Wu, Eric Q Xie, Jipan Producer: 20160722 In: Journal of blood medicine vol. 7 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	6.	BAY 94-9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results. [electronic resource] by Lalezari, Shadan Reding, Mark T Pabinger, Ingrid Holme, Pal Andre Negrier, Claude Chalasani, Pavani Shin, Ho-Jin Wang, Maria Tseneklidou-Stoeter, Despina Maas Enriquez, Monika Producer: 20200331 In: Haemophilia : the official journal of the World Federation of Hemophilia vol. 25 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	7.	Immunoglobulin G treatment of postcardiac surgery patients with score-identified severe systemic inflammatory response syndrome--the ESSICS study. [electronic resource] by Werdan, Karl Pilz, Günter Müller-Werdan, Ursula Maas Enriquez, Monika Schmitt, Dierk V Mohr, Friedrich-Wilhelm Neeser, Gertraud Schöndube, Friedrich Schäfers, Hans-Joachim Haverich, Axel Fraunberger, Peter Andersson, Jan Kreuzer, Eckart Thijs, Lambert G Producer: 20080529 In: Critical care medicine vol. 36 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)